Treatment expectations of individuals with metastatic prostate cancer and their health care providers often do not match.
Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
African American men choosing active surveillance for their low-grade prostate cancer have overall poorer health than non-African American men undergoing active surveillance.
Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.
A significant difference exists in the failure to follow-up rates among patients undergoing active surveillance at university-based hospitals versus safety-net hospitals.